Psych|OS Photo "The Bernhard Case"
Super Large Images:
Lilly 1112 | .zip
Lilly 4117| .zip
Hartware Dortmund Catalogue
Text by Domenico Quaranta
Zyprexa Lilly 111250x50, digital print on canvas, 2005, Edition of 3 + 1.a.p.
digital print on canvas, 2006, Edition of 3 + 1 a.p.
Zyprexa Lilly 4117
digital ink print on canvas, 2005, Edition of 3 + 1 a.p.
digital ink print on canvas, 2006, Edition of 3 + 1 a.p.
Olanzapine (Zyprexa®, Zydis®, or in a combination with fluoxetine as Symbyax®) was the second atypical antipsychotic to gain FDA approval and has become one of the most commonly used atypical antipsychotics. Olanzapine has been FDA approved for the treatment of schizophrenia, acute mania in bipolar disorder, agitation associated with schizophrenia and bipolar disorder, and as maintenance treatment in bipolar disorder. Olanzapine is manufactured and marketed by the pharmaceutical company Eli Lilly and Company.
Olanzapine can also be used to treat anxiety, although it is not commonly recommended for that purpose due to the strong side effects and expense. In particular, unlike benzodiazapenes, antipsychotics are non-addictive. Some psychiatrists have also been known to prescribe it to eating disorder patients, due both to its mood stabilising effects and tendency to increase weight.